Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Equity Ratio (2017 - 2025)

Serina Therapeutics' Equity Ratio history spans 9 years, with the latest figure at 0.14 for Q3 2025.

  • For Q3 2025, Equity Ratio changed N/A year-over-year to 0.14; the TTM value through Sep 2025 reached 0.14, changed N/A, while the annual FY2024 figure was 0.08, 102.1% up from the prior year.
  • Equity Ratio for Q3 2025 was 0.14 at Serina Therapeutics, up from 0.08 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.14 in Q3 2025 and bottomed at 11.66 in Q4 2022.
  • The 5-year median for Equity Ratio is 3.07 (2021), against an average of 3.61.
  • The largest annual shift saw Equity Ratio plummeted 2522.49% in 2021 before it surged 102.1% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 3.77 in 2021, then plummeted by 209.59% to 11.66 in 2022, then skyrocketed by 69.11% to 3.6 in 2023, then soared by 102.1% to 0.08 in 2024, then surged by 87.67% to 0.14 in 2025.
  • Per Business Quant, the three most recent readings for SER's Equity Ratio are 0.14 (Q3 2025), 0.08 (Q4 2024), and 1.53 (Q2 2024).